Because the myeloid differentiation antigen, CD33, is expressed on at least a subset of AML blasts in almost all patients and possibly on underlying leukemia stem cells in some [6,7,8,9,10,11], immunotherapies targeting CD33 have long been pursued to improve these outcomes [10,12]. Here, CD33 is linked to leukemia.